Intervention not reported
Pain VAS (0 to 100) Short‐term · patients with non‐specific chronic low back pain
1 finding from 1 review
Intervention not reported
Disability Multiple scales (0 to 100) Short‐term · patients with non‐specific chronic low back pain
1 finding from 1 review
Intervention not reported
Pain VAS (0 to 100) Short‐term · patients with non‐specific chronic low back pain
1 finding from 1 review
Intervention not reported
Disability Multiple scales (0 to 100) Short‐term · patients with non‐specific chronic low back pain
1 finding from 1 review
Intervention not reported
Pain VAS (0 to 100) Short‐term · patients with non‐specific chronic low back pain
1 finding from 1 review
Intervention not reported
Disability Multiple scales (0 to 100) Short‐term · patients with non‐specific chronic low back pain
1 finding from 1 review
Intervention not reported
Disability Multiple scales (0 to 100) Short‐term · patients with non‐specific chronic low back pain
1 finding from 1 review
Intervention not reported
Pain VAS (0 to 100) Short‐term · patients with non‐specific chronic low back pain
1 finding from 1 review
Global state: not improved ‐ short‐term GAF · patients with schizophrenia
CHLORPROMAZINE may leads to lower global state: Not improved (short term) compared with RESERPINE (low certainty).
1 finding from 1 review
Mental state: Not improved (paranoid distortion) Multidimentional Scale for Rating Psychiatric Patients (short term) · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes mental state: Not improved (paranoid distortion) Multidimentional… compared with RESERPINE (very low certainty).
1 finding from 1 review
Functioning: not improved occupational adjustment (short term) · patients with schizophrenia
CHLORPROMAZINE showed no clear difference in functioning: not improved occupational adjustment (short term) compared with RESERPINE (moderate certainty).
1 finding from 1 review
Adverse events ‐ toxic reaction (short term) · patients with schizophrenia
CHLORPROMAZINE showed no clear difference in adverse events ‐ toxic reaction (short term) compared with RESERPINE (moderate certainty).
1 finding from 1 review
Leaving the study early ‐ due to adverse effects (short term) · patients with schizophrenia
CHLORPROMAZINE showed no clear difference in leaving the study early ‐ due to adverse effects (short term) compared with RESERPINE (moderate certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Patients with acute low‐back pain
1 finding from 1 review
Disability 1 week (immediate term) (RMDQ 0 to 24) · Patients with acute low‐back pain
1 finding from 1 review
Change in pain intensity from baseline on VAS (0 to 100) short‐term · people with low back pain with sciatica
It is very uncertain whether NSAIDs changes change in pain intensity from baseline on VAS (0 to 100) short‐term compared with placebo (very low certainty).
1 finding from 1 review
Global Improvement short‐term · people with low back pain with sciatica
NSAIDs may leads to higher global Improvement short‐term compared with placebo (low certainty).
1 finding from 1 review
Side effects short‐term · people with low back pain with sciatica
NSAIDs may leads to higher side effects short‐term compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Short‐term maternal morbidity · women with term breech delivery
The intervention may leads to higher short‐term maternal morbidity (low certainty).
1 finding from 1 review
Quality of Life Manchester Short Assessment (MANSA) · patients with people with severe mental illnesses
1 finding from 1 review